Chris Rusconi

WORK HISTORY

EDUCATION

SKILLS

ABOUT CHRIS RUSCONI

Biotechnology executive and advisor with 20+ years of experience building platform biotech companies and creating clinical-stage assets across multiple therapeutic modalities.Adaptable leader who has served as Chief Scientific & Development Officer in both traditional biotechnology companies and technology-enabled biotechs, transforming platform technologies into differentiated products and scalable pipelines across oligonucleotide medicines, small molecules, and gene therapy, and across rare, cardiometabolic, renal, neurologic, and ocular diseases.Led science, development, and technical diligence from company formation through private financings, IPO, and public-company scale to valuations exceeding $400M, including leading the scientific diligence for the Regado–Tobira reverse merger, preceding Allergan’s $1.7B acquisition of Tobira Therapeutics.Known for aligning platform strategy, pipeline design, IP creation, and regulatory execution to drive clear value inflection points for investors and partners. Experience spans IND-enabling through Phase 3 development, global FDA/EMA engagement, and strategic pharmaceutical partnerships.Inventor on 70+ issued and pending patents and author of 40+ peer-reviewed publications.Extensive experience advising biotech leadership teams and investors—and serving in board and scientific advisory roles—on R&D strategy, diligence, and discovery-to-clinic execution to de-risk science and accelerate value creation.